Optimizing conventional medical therapies in inflammatory bowel disease in 2014

Anil Kumar Asthana, Miles P. Sparrow, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.

Original languageEnglish
Pages (from-to)1002-1010
Number of pages9
JournalCurrent Drug Targets
Issue number11
Publication statusPublished - 2014
Externally publishedYes


  • Allopurinol
  • Aminosalicylates
  • Anti-tumor necrosis factor agents
  • Corticosteroids
  • Therapeutic drug monitoring
  • Thioguanine nucleotides
  • Thiopurines

Cite this